LIAISON XL MUREX HBsAg Qual and LIAISON XL MUREX Control HBsAg Qual
DiaSorin, Inc. · Decision date Aug 28, 2025
What did the FDA decide?
FDA records P190017/S028 as a supplement to PMA P190017, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 28, 2025.
FDA approval order statement
to add another packaging line in one of DiaSorins locations
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Aug 28, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P190017/S028
- Regulatory pathway
- PMA supplement
- Applicant
- DiaSorin, Inc.
- Product code
- LOM
- Decision code
- OK30
- Decision date
- Aug 28, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).
- Applicant
- DiaSorin, Inc.
- Product code
- LOM
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190017/S028 received
Application receipt date recorded by FDA.
P190017/S027 · Related supplement
LIAISON MUREX HBsAg Qual, LIAISON MUREX Control HBsAg Qual and LIAISON MUREX HBsAg Confirmatory
P190017/S028 · FDA decision
30-Day Notice
P190017/S026 · Related supplement
LIAISON XL MUREX HBsAg Qual and LIAISON XL MUREX Control HBsAg Qual
Timeline entries are records held by MedtechLedger for P190017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | PMA supplement | Aug 21, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Oct 10, 2025 | FDA |
Explore the linked device profile
Other records with product code LOM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | 510(k) clearance | Jun 4, 2026 | FDA | |
Atellica IM Hepatitis B core IgM (aHBcM)P030040/S024 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
Atellica IM Hepatitis B e Antigen (HBeAg)P090024/S013 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | Oct 17, 2025 | FDA | |
| Siemens Corp. | PMA supplement | Oct 17, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
DiaSorin, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1951 Northwestern Ave., Stillwater, MN, 55082
Sources and methodology
- Original FDA record: P190017/S028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



